Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy
Published 2021. This article is a U.S.Government work and is in the public domain in the USA..
BACKGROUND: Hepatitis delta virus (HDV) infection is the most aggressive form of chronic viral hepatitis. Response rates to therapy with 1- to 2-year courses of pegylated interferon alpha (peginterferon) treatment are suboptimal.
AIMS: To evaluate the long-term outcomes of patients with chronic hepatitis D after an extended course of peginterferon.
METHODS: Patients were followed after completion of trial NCT00023322 and classified based on virological response defined as loss of detectable serum HDV RNA at last follow-up. During extended follow-up, survival and liver-related events were recorded.
RESULTS: All 12 patients who received more than 6 months of peginterferon in the original study were included in this analysis. The cohort was mostly white (83%) and male (92%) and ranged in age from 18 to 58 years (mean = 42.6). Most patients had advanced but compensated liver disease at baseline, a median HBV DNA level of 536 IU per mL and median HDV RNA level of 6.86 log10 genome equivalents per mL. The treatment duration averaged 6.1 years (range 0.8-14.3) with a total follow-up of 8.8 years (range 1.7-17.6). At last follow-up, seven (58%) patients had durable undetectable HDV RNA in serum, and four (33%) cleared HBsAg. Overall, one of seven (14%) responders died or had a liver-related event vs four of five (80%) non-responders.
CONCLUSIONS: With further follow-up, an extended course of peginterferon therapy was found to result in sustained clearance of HDV RNA and favourable clinical outcomes in more than half of patients and loss of HBsAg in a third.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 54(2021), 2 vom: 21. Juli, Seite 176-182 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hercun, Julian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3WJQ0SDW1A |
|---|
| Anmerkungen: |
Date Completed 09.08.2021 Date Revised 01.03.2023 published: Print-Electronic ClinicalTrials.gov: NCT00023322 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.16408 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325973121 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325973121 | ||
| 003 | DE-627 | ||
| 005 | 20231225193601.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.16408 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM325973121 | ||
| 035 | |a (NLM)34048594 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hercun, Julian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2021 | ||
| 500 | |a Date Revised 01.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT00023322 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published 2021. This article is a U.S.Government work and is in the public domain in the USA. | ||
| 520 | |a BACKGROUND: Hepatitis delta virus (HDV) infection is the most aggressive form of chronic viral hepatitis. Response rates to therapy with 1- to 2-year courses of pegylated interferon alpha (peginterferon) treatment are suboptimal | ||
| 520 | |a AIMS: To evaluate the long-term outcomes of patients with chronic hepatitis D after an extended course of peginterferon | ||
| 520 | |a METHODS: Patients were followed after completion of trial NCT00023322 and classified based on virological response defined as loss of detectable serum HDV RNA at last follow-up. During extended follow-up, survival and liver-related events were recorded | ||
| 520 | |a RESULTS: All 12 patients who received more than 6 months of peginterferon in the original study were included in this analysis. The cohort was mostly white (83%) and male (92%) and ranged in age from 18 to 58 years (mean = 42.6). Most patients had advanced but compensated liver disease at baseline, a median HBV DNA level of 536 IU per mL and median HDV RNA level of 6.86 log10 genome equivalents per mL. The treatment duration averaged 6.1 years (range 0.8-14.3) with a total follow-up of 8.8 years (range 1.7-17.6). At last follow-up, seven (58%) patients had durable undetectable HDV RNA in serum, and four (33%) cleared HBsAg. Overall, one of seven (14%) responders died or had a liver-related event vs four of five (80%) non-responders | ||
| 520 | |a CONCLUSIONS: With further follow-up, an extended course of peginterferon therapy was found to result in sustained clearance of HDV RNA and favourable clinical outcomes in more than half of patients and loss of HBsAg in a third | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Intramural | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hepatitis B Surface Antigens |2 NLM | |
| 650 | 7 | |a RNA, Viral |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 700 | 1 | |a Kim, Grace E |e verfasserin |4 aut | |
| 700 | 1 | |a Da, Ben L |e verfasserin |4 aut | |
| 700 | 1 | |a Rotman, Yaron |e verfasserin |4 aut | |
| 700 | 1 | |a Kleiner, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Glenn, Jeffrey S |e verfasserin |4 aut | |
| 700 | 1 | |a Hoofnagle, Jay H |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Heller, Theo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 54(2021), 2 vom: 21. Juli, Seite 176-182 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2021 |g number:2 |g day:21 |g month:07 |g pages:176-182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.16408 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2021 |e 2 |b 21 |c 07 |h 176-182 | ||